Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis

• Status: Unknown status
• Trial end date: 2019-12-15
• Target enrollment: 0
• Participant gender: All

Summary

4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Psoriasis Treatment Center of Central New Jersey
• Collaborator: LEO Pharma
• Treatments: Adalimumab; Betamethasone; Betamethasone-17,21-dipropionate; Calcipotriene; Calcitriol; Etanercept

Criteria

Inclusion Criteria:

• Male or female adult ≥ 18 years of age;

• Diagnosis of chronic plaque-type

• Patient with 2-10% BSA

• Physician Global Assessment of 2 or greater

• Patient has been treated with etanercept or adalimumab for a minimum of 24 weeks

Exclusion Criteria:

• ˂2 or >10% BSA

• PGA <2

• Patient not receiving etanercept or adalimumab, or receiving etanercept or adalimumab <24weeks